CACI Continues to Deliver Effective Mission Support to U.S. Africa Command
We are uniquely equipped to support USAFRICOM in countering emerging threats.
'CACI's experienced, flexible, and responsive global workforce understands Africa's complex security landscape. We leverage the most innovative technologies and on-the-ground capabilities to significantly enhance USAFRICOM's ability to execute its critical mission,' said John Mengucci, CACI President and Chief Executive Officer. 'We are uniquely equipped to support USAFRICOM in countering emerging threats, strengthening regional partnerships, and driving unparalleled efficiency and operational excellence.'
CACI is renowned for delivering unrivaled expertise to address its customers' most difficult challenges and requirements, leveraging its decades of mission knowledge coupled with cutting-edge practices and tools. Under this contract, CACI will continue improving force protection, mission assurance, and effective execution of theater strategy while also enhancing command relationships.
About CACI
At CACI International Inc (NYSE: CACI), our 25,000 talented and dynamic employees are ever vigilant in delivering distinctive expertise and differentiated technology to meet our customers' greatest challenges in national security. We are a company of good character, relentless innovation, and long-standing excellence. Our culture drives our success and earns us recognition as a Fortune World's Most Admired Company. CACI is a member of the Fortune 500™ list of largest companies, the Russell 1000 Index, and the S&P MidCap 400 Index. For more information, visit us at www.caci.com.
There are statements made herein which do not address historical facts, and therefore could be interpreted to be forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to factors that could cause actual results to differ materially from anticipated results. The factors that could cause actual results to differ materially from those anticipated include, but are not limited to, the risk factors set forth in CACI's Annual Report on Form 10-K for the fiscal year ended June 30, 2024, and other such filings that CACI makes with the Securities and Exchange Commission from time to time. Any forward-looking statements should not be unduly relied upon and only speak as of the date hereof.
CACI-Contract Award-Business Wire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Bruker, Viatris, Sotera Health Company, Align Technology, and Omnicell Stocks Trade Up, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Research Tools & Consumables company Bruker (NASDAQ:BRKR) jumped 3.7%. Is now the time to buy Bruker? Access our full analysis report here, it's free. Generic Pharmaceuticals company Viatris (NASDAQ:VTRS) jumped 3.1%. Is now the time to buy Viatris? Access our full analysis report here, it's free. Research Tools & Consumables company Sotera Health Company (NASDAQ:SHC) jumped 3.1%. Is now the time to buy Sotera Health Company? Access our full analysis report here, it's free. Dental Equipment & Technology company Align Technology (NASDAQ:ALGN) jumped 3.3%. Is now the time to buy Align Technology? Access our full analysis report here, it's free. Healthcare Technology for Providers company Omnicell (NASDAQ:OMCL) jumped 3.1%. Is now the time to buy Omnicell? Access our full analysis report here, it's free. Zooming In On Bruker (BRKR) Bruker's shares are very volatile and have had 20 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 8 days ago when the stock dropped 7.4% on the news that the company reported disappointing second-quarter results and lowered its full-year financial forecast, citing challenging market demand. The company's revenue for the quarter landed at $797.4 million, which missed analyst expectations. A key metric, organic revenue, which measures sales growth from a company's core operations, fell by 7.0%. Earnings per share (EPS), a measure of profitability, came in at $0.32, significantly below the consensus estimate of $0.42. In response to the weak performance, Bruker cut its full-year guidance, and now projected an organic revenue decline between 2% and 4%. Management pointed to decreased demand for life-science research instruments, especially from U.S. academic and biopharma customers, as the primary cause. The company also announced a cost-saving plan intended to reduce annual expenses. Bruker is down 45.9% since the beginning of the year, and at $31.80 per share, it is trading 55% below its 52-week high of $70.67 from September 2024. Investors who bought $1,000 worth of Bruker's shares 5 years ago would now be looking at an investment worth $723.25. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
Yahoo
26 minutes ago
- Yahoo
Thermo Fisher, ICU Medical, CONMED, Pediatrix Medical Group, and IQVIA Stocks Trade Up, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Research Tools & Consumables company Thermo Fisher (NYSE:TMO) jumped 3%. Is now the time to buy Thermo Fisher? Access our full analysis report here, it's free. Medical Devices & Supplies - Cardiology, Neurology, Vascular company ICU Medical (NASDAQ:ICUI) jumped 3.4%. Is now the time to buy ICU Medical? Access our full analysis report here, it's free. Surgical Equipment & Consumables - Diversified company CONMED (NYSE:CNMD) jumped 3.1%. Is now the time to buy CONMED? Access our full analysis report here, it's free. Specialized Medical & Nursing Services company Pediatrix Medical Group (NYSE:MD) jumped 4.1%. Is now the time to buy Pediatrix Medical Group? Access our full analysis report here, it's free. Drug Development Inputs & Services company IQVIA (NYSE:IQV) jumped 3%. Is now the time to buy IQVIA? Access our full analysis report here, it's free. Zooming In On Pediatrix Medical Group (MD) Pediatrix Medical Group's shares are somewhat volatile and have had 14 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 4 months ago when the stock dropped 6.7% on the news that President Trump announced "reciprocal tariffs" on all US imports, set at a minimum rate of 10%. Markets reacted negatively to the announcement, reflecting deep concerns among investors about the broader economic implications. The tariffs were likely seen as a significant threat to global trade flows, with the potential to slow economic growth, drive up consumer prices, and spark retaliatory measures. Wedbush analyst Dan Ives captured the prevailing market anxiety, stating, "We would characterize this slate of tariffs as 'worse than the worst case scenario' the Street was fearing." His comment highlighted how the scope and severity of the tariffs far exceeded Wall Street's expectations, adding a new layer of uncertainty for businesses and investors. Pediatrix Medical Group is up 13.1% since the beginning of the year, but at $14.74 per share, it is still trading 14.5% below its 52-week high of $17.23 from February 2025. Investors who bought $1,000 worth of Pediatrix Medical Group's shares 5 years ago would now be looking at an investment worth $726.11. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
Yahoo
26 minutes ago
- Yahoo
Centene, RadNet, Evolent Health, Illumina, and Charles River Laboratories Shares Are Soaring, What You Need To Know
What Happened? A number of stocks jumped in the morning session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Health Insurance Providers company Centene (NYSE:CNC) jumped 3.1%. Is now the time to buy Centene? Access our full analysis report here, it's free. Testing & Diagnostics Services company RadNet (NASDAQ:RDNT) jumped 3.3%. Is now the time to buy RadNet? Access our full analysis report here, it's free. Healthcare Technology for Providers company Evolent Health (NYSE:EVH) jumped 3.2%. Is now the time to buy Evolent Health? Access our full analysis report here, it's free. Genomics & Sequencing company Illumina (NASDAQ:ILMN) jumped 3.1%. Is now the time to buy Illumina? Access our full analysis report here, it's free. Drug Development Inputs & Services company Charles River Laboratories (NYSE:CRL) jumped 3.1%. Is now the time to buy Charles River Laboratories? Access our full analysis report here, it's free. Zooming In On RadNet (RDNT) RadNet's shares are quite volatile and have had 15 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was about 2 months ago when the stock gained 5.2% on the news that the major indices rebounded (Nasdaq +1.5%, S&P 500 +1.0%) as reports pointed to easing tensions between Israel and Iran. The Wall Street Journal said senior Iranian officials had signaled a willingness to restart stalled nuclear talks, on the condition that Washington refrain from joining Israel's ongoing strikes. This development triggered a significant decline in oil prices, easing inflation concerns. Also, it is possible some investors were buying the dip following the sell-off at the end of the previous week. RadNet is down 9.5% since the beginning of the year, and at $63.49 per share, it is trading 26.5% below its 52-week high of $86.38 from November 2024. Investors who bought $1,000 worth of RadNet's shares 5 years ago would now be looking at an investment worth $3,565. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
